My hunch is the control arm will be switched to EPA, but will not continue.
Those are contradictory statements - if control is switched to EPA, by definition the study continues, but will be unblinded at that point - that actually might be a good idea, assuming interim data is used to approve R-IT indication, to see if the old control group event rate changes after the switch - as long as approval is fast enough for AMRN to afford to continue.